{
    "organizations": [],
    "uuid": "ecf477a6870c9e7d39ff8d076b8e52e7e5d6aca9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-provides-update-on-keynote-4/brief-merck-provides-update-on-keynote-407-trial-idUSASC09ZF9",
    "ord_in_thread": 0,
    "title": "Merck Provides Update On Keynote-407 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Merck & Co Inc:\n* MERCK PROVIDES UPDATE ON KEYNOTE-407 TRIAL\n* MERCK - PHASE 3 KEYNOTE-407 TRIAL MET A PRE-SPECIFIED SECONDARY ENDPOINT OF ORR IN AN EARLY COHORT OF PARTICIPANTS AT AN INTERIM ANALYSIS\n* MERCK & CO INC - NOW EXPECTS THAT AN ADDITIONAL INTERIM ANALYSIS WILL BE CONDUCTED PRIOR TO ASCO\n* MERCK - BASED ON KEYNOTE-407 TRIAL DATA, RECENTLY SUBMITTED A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\nOur ",
    "published": "2018-05-03T18:54:00.000+03:00",
    "crawled": "2018-05-04T16:51:28.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "provides",
        "update",
        "trial",
        "merck",
        "phase",
        "trial",
        "met",
        "secondary",
        "endpoint",
        "orr",
        "early",
        "cohort",
        "participant",
        "interim",
        "analysis",
        "merck",
        "co",
        "inc",
        "expects",
        "additional",
        "interim",
        "analysis",
        "conducted",
        "prior",
        "asco",
        "merck",
        "based",
        "trial",
        "data",
        "recently",
        "submitted",
        "supplemental",
        "biologics",
        "license",
        "application",
        "fda",
        "source",
        "text",
        "eikon"
    ]
}